Business Wire

Blackrock Microsystems Licenses Wyss Center’s Real-time Neural Signal Processing Platform

Share

The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications. The agreement follows a long-standing collaborative relationship and represents the first of many important neurotechnology developments the Wyss Center and Blackrock Microsystems intend to advance together.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005373/en/

The real-time neural signal processing platform will extend the reach of brain-computer interface applications. (Photo: Wyss Center)

The real-time neural signal processing platform will extend the reach of brain-computer interface applications. (Photo: Wyss Center)

“One limitation of neural signal processing applications is that there is no single software platform that directly works with the multiple devices collecting brain signals. Researchers and clinicians have to develop their own software to analyze the signals from a patient, which limits effectiveness and slows down the implementation of solutions to the clinic,” said David Ibanez, Ph.D., Brain Machine Interface Scientist at the Wyss Center. Ibanez has been leading the Wyss Center’s software platform development efforts over recent months.

Optimized for use with implantable, high-channel count brain-computer interfaces (BCIs), the Wyss Center’s high-performance data analysis platform, called NeuroKey, is an important building block for complete real-time neural interface research and clinical applications, including restoration of movement, communication and control of assistive devices.

The medical-grade platform is compatible with commercial hardware and sensors and can be adapted to custom-made devices. NeuroKey has the potential to accelerate BCI technology research and development for clinical deployment in the lab and at home.

“Access to enabling devices at home, would give me greater independence and freedom,” said Ian Burkhart. Known as a BCI Pioneer, Ian has an enabling neural interface developed by Blackrock Microsystems. He sustained a spinal cord injury during a diving accident in 2010. "Currently BCI devices can only be used under extreme supervision in controlled environments, however, this innovation from Blackrock Microsystems and the Wyss Center pushes research to a stage where these devices can advance into the real world.”

The partnership between the Wyss Center and Blackrock Microsystems is a strong example of the Center’s translational approach. It combines the technical talent and research and development efforts of the Center’s staff with the clinical and market knowledge of Blackrock Microsystems, who has been the leading provider of reliable invasive brain computer interface technology to researchers and BCI Pioneers (tetraplegic patients) for more than a decade.

“Blackrock Microsystems is proud to be collaborating with the Wyss Center in an effort to bring life-changing innovation and neuro technology to patients,” said Marcus Gerhardt, MPhil, MA, Blackrock Microsystem’s co-founder and CEO.

“We hope that this is the first of many joint neurotechnology developments with Blackrock Microsystems, that will have a big impact on many people’s lives,” added Wyss Center’s CEO Mary Tolikas, Ph.D., MBA.

ENDS

About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland

The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.

The Wyss Center staff, together with the Center’s academic and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroradiology and neurotechnology, to reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease and to accelerate the development of devices and therapies for unmet medical needs.

The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.

www.wysscenter.ch/

About Blackrock Microsystems LLC

Blackrock Microsystems, based in Salt Lake City, Utah, was founded in 2008 and is the world’s leading provider of technology in the neuroscience, neural engineering, and neural prosthetics space. The company’s technology is at the core of worldwide innovations in Brain-Machine Interfaces (BMI/BCI), implantable bionic technologies and epilepsy diagnostics. Most impactful implantations of the Utah Array have been in some tetraplegic individuals from University of Pittsburgh’s Nathan Copeland, who controlled a prosthetic arm to fist bump US President Barack Obama in 2016; Ohio State University’s Ian Burkhart who is learning to control an automobile, and CalTech’s Nancy Smith who is learning to play a virtual piano. Seemingly easy tasks, all have used the Utah Array to translate their thoughts into action to restore function.

Image
Download (20 MB)

Contact information

MEDIA CONTACTS:
Wyss Center
Jo Bowler, Media and Public Relations Manager
+41 (0) 58 201 03 09
johanna.bowler@wysscenter.ch

Blackrock Microsystems
Shilo Case, Marketing Manager
+1 (801) 582-5533
Scase@blackrockmicro.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology16.4.2021 22:00:00 CEST | Press release

Bollé Safety, world leader in the design and manufacture of protective eyewear, presents its Healthcare division dedicated to all healthcare professionals. Its range of protective eyewear with anti-fog and anti-scratch PLATINUM® coating provides highly exposed employees with the highest levels of protection, clarity, and vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005009/en/ @BolléSafety - A.Childeric Viruses & infections’ protection Bollé Safety offers certified products compliant with the most stringent international standards. Its anti-fog PPE product range is tailored to protect professionals who are at high risk of being exposed to bodily fluids when providing care to patients. It is the company’s shared commitment to provide the highest quality protection for all healthcare workers. The importance of a clear vision Bollé Safety’s unique and exclusive permanent double sided anti-fog and anti-scratch PLA

Zeepay Ghana Acquires Mangwee Mobile Money in Zambia16.4.2021 19:55:00 CEST | Press release

Zeepay, the leading African Challenger Fintech with operations in over 10 African countries today acquired a 51 percent stake in Mangwee Mobile Money in Zambia. In a private placement Zeepay and Mangwee agreed to a sale of 51 percent of Mangwee shares to Zeepay. The deal makes Zeepay Ghana the majority shareholder of the entity. Mangwee has been in operations since 2018, and was initially set up to operate as an alternative wallet targeting university students in Zambia with the aim of assisting to drive the cost of mobile money services downward. Zeepay is the leading African challenger fintech with operations across 20 African countries and 30 day active in 10 of them. The company specializes in paying remittances into mobile money wallets across Africa and is regulated by both Bank of Ghana as an EMI issuer and in the UK as a Money Transfer Operator, by the Financial Conduct Authority. The merger is the first of its kind; that two Indigenous African fintechs into Mobile Money operat

CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future16.4.2021 18:29:00 CEST | Press release

Climate change is not taking a break from wreaking havoc in 2020, with the joint highest global temperatures on record, rampant bushfires, the faster rates of sea level rise and the extinction of some species. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005435/en/ Under this circumstance, Chinese President Xi Jinping, French President Emmanuel Macron, and German Chancellor Angela Merkel held a virtual meeting Friday on climate change, ahead of the Leaders' Climate Summit on Earth Day convened by the U.S., scheduled next week. Emphasizing that he always advocates building a community with a shared future for mankind, the Chinese president voiced his willingness to strengthen cooperation with France and Germany on climate change. "Tackling climate change is a common cause for all mankind and it should not become a geopolitical bargaining chip, a target for attacking other countries, or an excuse for trade barriers," h

Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 202116.4.2021 15:30:00 CEST | Press release

Colicity Inc. (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, completed on February 26, 2021 (the “Offering”) may elect to separately trade the Class A common stock and warrants included in the units commencing on or about April 16, 2021. Any Units not separated will continue to trade on The Nasdaq Capital Market under the symbol “COLIU,” and the Class A common stock and warrants will separately trade on The Nasdaq Capital Market under the symbols “COLI” and “COLIW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A common stock and warrants. This press release shall not constitute an o

Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS16.4.2021 10:00:00 CEST | Press release

Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the investigational Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib significantly reduced blood neurofilament light chain (NfL) levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS). Elevated blood NfL levels have been shown to be associated with damage to neurons and inflammation and may predict future brain atrophy and disease progression. “Blood NfL is a biomarker that may allow monitoring of disease activity and treatment response, which could be less burdensome and more sensitive than other standard clinical measures for MS patients,” said Prof. Jens Kuhle, MD, PhD, Head Multiple Sclerosis Centre, University Hospital Basel. “These data provide key insights into the role evobrutinib may play in modulating the clinical course of MS and fur

IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company15.4.2021 22:15:00 CEST | Press release

IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations. In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results. “As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ seri

Algorand and BridgeTower Capital Announce Strategic Partnership15.4.2021 22:14:00 CEST | Press release

BridgeTower Capital, a global private equity firm, focusing on traditional private equity investments and blockchain and DeFi markets, announced today a partnership with Algorand. Algorand, the creator of the world’s first pure proof-of-stake foundational blockchain, is a leading blockchain technology company accelerating the convergence of decentralized and traditional finance. BridgeTower will use Algorand’s technology as the underlying blockchain solution to issuance of the BridgeTower Capital tokenized digital security. It will also use Algorand as a preferred blockchain for BridgeTower products and services. Beyond the elementary requirement of an open, public network, Algorand’s technology enables a set of high performing Layer-1 blockchains that provide security, scalability, complete transaction finality, built in privacy, Co-Chains, and advanced smart contracts. “Algorand was a clear choice given their technology, team and leadership position in the digital marketplace,” said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom